The combination of CAB LA and RPV LA has been shown in clinical trials in virologically suppressed adults living with HIV to be safe, well-tolerated and efficacious as a complete…
Read More
Adolescents have poorer treatment outcomes including higher loss to follow-up, lower treatment adherence, poorer virological suppression and higher mortality than older people living with HIV. Some of the adherence challenges…
Read More
This is a Phase III, open-label, multi-center trial with a cluster-randomized superiority design. The purpose of the study is to compare the efficacy and safety of 26 weeks of Delamanid…
Read More
